此次合作不仅限于SIM0505的全球开发，还包括一项独特的双向技术合作。NextCure获得授权使用先声 再明专有的ADC连接子和TOPOi有效载荷，用于其一款临床前阶段新靶点ADC的开发，而先声再明将 拥有这款新靶点ADC在大中华区的权利。 7.45亿美元背后的中国创新药出海新范式 此次交易金额高达7.45亿美元，是先声药业创新出海战略的又一重要里程碑，也是中国原研创新药通过 BD（业务发展）模式成功走向全球的缩影。 一纸7.45亿美元的合约，将中国原研抗体偶联药物推上全球抗癌新战场。北京时间6月16日，先声药业 旗下抗肿瘤创新药公司先声再明与美国生物制药公司NextCure共同宣布，双方就靶向CDH6的抗体药物 偶联物（ADC）新药SIM0505达成战略合作。 根据协议，NextCure获得SIM0505除大中华区以外的全球开发和商业化权利。先声再明将获得最高达 7.45亿美元的相关付款，包括首付款、开发及销售里程碑款项，并将额外获得基于该产品在大中华区以 外地区净销售额的高至双位数的分级特许权使用费。 CDH6蓝海角逐，中国原研ADC的技术突围 当前全球尚无靶向CDH6的药物上市，该靶点因在卵巢癌、肾癌 ...

Core Viewpoint - The recent surge in the Hong Kong innovative drug sector, particularly for Xiansheng Pharmaceutical, is driven by favorable factors such as the cyclical resurgence of COVID-19 and record-breaking domestic innovative drug business development (BD) deals [1] Group 1: Stock Performance - Xiansheng Pharmaceutical's stock price has experienced a continuous rise since May 16, achieving a maximum increase of 28.33% by May 21, with a cumulative increase of nearly 50% year-to-date [1] - The stock has shown significant trading activity, with over 25 million shares traded on three consecutive days from May 19 to 21, indicating strong market interest [4] Group 2: Business Development Potential - The recent $60.5 billion BD deal between Innovent Biologics and Pfizer has spotlighted the potential of Chinese innovative drugs, with Xiansheng Pharmaceutical being a key player in this growth [2] - Xiansheng Pharmaceutical has developed multiple ADC (antibody-drug conjugate) candidates targeting various biomarkers, with products like SCR-A006 showing Best-in-Class potential [2] Group 3: International Expansion - Xiansheng Pharmaceutical has established a track record in international markets, with its first overseas deal for SIM0278 setting a record for domestic autoimmune drug BD at the time [3] - The company has secured a licensing agreement exceeding $1 billion for SIM0500 with AbbVie, currently undergoing clinical trials in the U.S. and China [3] Group 4: Innovation and R&D - The company has invested over 8.5 billion yuan in R&D over six years, developing over 60 innovative drug candidates across various therapeutic areas [5] - Three new drug molecules are in the NDA approval process, while four are in Phase III clinical trials, indicating a robust pipeline [5] - The anticipated launch of significant new drugs will further enhance the company's position in the global biopharmaceutical market [5]